Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.59 |
| ▸ | BCR | P11274 | 4/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 15/20 | 0.48 |
| ▸ | RAF1 | P04049 | 10/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921674 | 1.00 | ABL1 (0.59) | ABL1BCRCSF1RKITBRAF | |
| SCHEMBL29921892 | 0.91 | ABL1 (0.72) | ABL1BCRCSF1RKITBRAF | |
| SCHEMBL29071349 | 0.91 | ABL1 (0.72) | ABL1BCRCSF1RKITBRAF | |
| SCHEMBL29071283 | 0.90 | BRAF (0.49) | ABL1BCRBRAFRAF1CYP2C9 | |
| SCHEMBL29921639 | 0.90 | BRAF (0.49) | ABL1BCRBRAFRAF1CYP2C9 | |
| SCHEMBL29071287 | 0.89 | ABL1 (0.48) | ABL1BCRBRAFRAF1 | |
| SCHEMBL29921421 | 0.89 | ABL1 (0.48) | ABL1BCRBRAFRAF1 | |
| SCHEMBL29921869 | 0.89 | ABL1 (0.60) | ABL1BCRCSF1RBRAFRAF1 | |
| SCHEMBL29071512 | 0.89 | ABL1 (0.60) | ABL1BCRCSF1RBRAFRAF1 | |
| SCHEMBL29921979 | 0.88 | BRAF (0.48) | ABL1BCRBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761801-A | Heterocyclic compounds having protein kinase inhibitory activity, pharmaceutical compositions containing the same, and methods of preparing and using the same | 四川科伦博泰生物医药股份有限公司 | 2023-09-15 | — | — | CN | disclosed |